A Call to Arms: Tools for HCV Treaters to Maximize HCV Cure Rates and Advance Toward HCV Elimination
  • CME
  • CE

Led by Norah Terrault, MD, MPH, a panel of experts including Jordan J. Feld, MD, MPH; Ira M. Jacobson, MD; Paul Y. Kwo, MD; and Christian B. Ramers, MD, MPH, provides an overview of the current state of HCV therapy, with an emphasis on the most recently approved options, and discusses 3 important focal points for achieving HCV elimination goals: increasing screening and diagnosis, treating populations that previously have been excluded from therapy, and curing the small but challenging population of patients who have experienced previous failure of direct-acting antiviral therapy.
Norah Terrault, MD, MPH
Program Director
Jordan J. Feld, MD, MPH
Ira M. Jacobson, MD
Paul Y. Kwo, MD
Christian B. Ramers, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Registered Nurses: 2.0 Nursing contact hours
Released: November 27, 2017 Expiration: November 26, 2018
Multimedia A Call to Arms: Tools for HCV Treaters to Maximize HCV Cure Rates and Advance Toward HCV Elimination
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Part 1: The Path to 100% HCV Elimination (9 minutes)
Norah Terrault, MD, MPH, provides a concise overview of the latest data on the HCV care cascade and highlights key barriers to achieving HCV elimination.
Launch Part 1: The Path to 100% HCV Elimination (9 minutes)
Part 2: The Toolkit to Achieve Cure (30 minutes)
Ira M. Jacobson, MD, provides a comprehensive overview of current therapy options across the genotypes for treatment-naive or peginterferon/ribavirin-experienced patients, with an emphasis on recently introduced regimens.
Launch Part 2: The Toolkit to Achieve Cure (30 minutes)
Part 3: Engaging the 50%: Increasing Screening and Diagnosis (20 minutes)
Jordan J. Feld, MD, MPH, outlines the critical role that primary care providers and other nonspecialists play in screening and diagnosis, linkage to specialist care, and/or treatment as well as the important role of specialists in engaging, training, and mentoring nonspecialists to support these efforts. Examples of how intensive testing and linkage programs have resulted in improvements across the cascade of care are also discussed.
Launch Part 3: Engaging the 50%: Increasing Screening and Diagnosis (20 minutes)
Part 4: Treating the 33%: Expanding Therapy to the Previously Excluded (25 minutes)
Christian B. Ramers, MD, MPH, discusses HCV management in young people who inject drugs, a key patient subgroup that has historically presented challenges to successful and durable HCV cure. This section includes practical guidance on important issues related to HCV care in these patients, including posttreatment prevention of reinfection and the concept of treatment as prevention.
Launch Part 4: Treating the 33%: Expanding Therapy to the Previously Excluded (25 minutes)
Part 5: Curing the 10%: Evolving Options for DAA-Experienced Patients (28 minutes)
Paul Y. Kwo, MD, reviews the latest evidence-based options for achieving HCV cure in DAA-experienced patients, including illustrative cases outlining how to select the best regimen for each patient and recent data on newly approved options in this setting.
Launch Part 5: Curing the 10%: Evolving Options for DAA-Experienced Patients (28 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply strategies to increase rates of HCV screening, diagnosis, and referral in primary care settings
  • Implement approaches to overcome barriers to HCV treatment and cure, including in underserved patient populations
  • Integrate current and emerging treatment options, including regimens appropriate for patients with previous treatment failure

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by:
Gilead Sciences

Information on this Educational Activity

Disclosure of Conflicts of Interests

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Norah Terrault, MD, MPH

Professor of Medicine and Surgery
Director, Viral Hepatitis Center
Division of Gastroenterology
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Gilead Sciences and Merck and funds for research support from AbbVie, Gilead Sciences, and Merck.

Faculty

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, ContraVir, Gilead Sciences, Janssen, and Merck and funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, and Merck.
Ira M. Jacobson, MD

Director of Hepatology
Department of Medicine
NYU School of Medicine
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received consulting fees from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Intercept, Merck, and Trek; fees for non‐CME/CE services from AbbVie, Gilead Sciences, Intercept, and Merck; and funds for research support from Genfit, Gilead Sciences, and Merck.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and funds for research support from AbbVie and Gilead Sciences.
Christian B. Ramers, MD, MPH

Assistant Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Assistant Medical Director
Division of Research/Special Populations
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, and Janssen; fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, and Merck; and funds for research support from Gilead Sciences.

Staff

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, and other healthcare providers who care for patients at risk of or infected with HCV.

Goal

The goal of this activity is to improve participants’ ability to cure HCV in individual patients and to contribute to efforts to eventually achieve HCV elimination.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

This educational activity for 2.0 contact hours is provided by Postgraduate Institute for Medicine.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 27, 2017, through November 26, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

CME-certified expert panel discussion of controversial issues in the management of HBV and HCV infection.

Norah Terrault, MD, MPH
Program Director
Paul Martin, MD Christian B. Ramers, MD, MPH Nancy Reau, MD, FAASLD, AGAF
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: July 6, 2018 Expiration: July 5, 2019

Norah Terrault, MD, MPH
Program Director
Paul Y. Kwo, MD Paul Martin, MD Christian B. Ramers, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: July 6, 2018 Expiration: July 5, 2019

Stefan Zeuzem, MD
Program Director
Jordan J. Feld, MD, MPH Hemant Shah, MD, MScCH HPTE
Released: June 15, 2018

Expert blog from Dr. Zobair M. Younossi offering perspective on new HCV and NAFLD/NASH data from the 2018 EASL International Liver Congress in Paris.

Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: June 4, 2018

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?